November 14, 2011 - Timothy Gardner (past-president of the American Heart Association) and Frank Sellke (Chairman of the Council on Cardiovascular Surgery and Anesthesia of the American Heart Association) review Cytograft’s first in human clinical results HERE.
July 15, 2011 - Cytograft highlighted in cover story in Medical Device Daily, found HERE.
June 27, 2011 - Dr. McAllister presents Cytograft's allogeneic vascular graft at the American Heart Association's prestigious Emerging Science series. The presentation can be found HERE.
June 20, 2011 - Cytograft publishes an article in Endovascular Today
December 8, 2010 - Dr. Nicolas L'Heureux, Cytograft's Chief Scientific Officer, opens and chairs the session Tissue Engineering and Regenerative Medicine in the Clinic at the North American meeting of TERMIS in Orlando, Florida.
November 22, 2010 - Dr. L'Heureux, co-founder and CSO of Cytograft, is featured in the "Industry Spotlight" of the Biomedical Engineering Society.
CLINICAL TRIALS

AV Access for Hemodialysis: Cytograft has clinical trials ongoing in both Europe and South America. The autologous version of the graft has a commercialization permit and can be sold in Germany. Clinical results from Cytograft’s lead product, the Lifeline™ graft for hemodialysis access have been reported in both the New England Journal of Medicine and the Lancet.

Lower Limb Bypass for Critical Limb Ischemia: The Lifeline™ graft will soon be available to a select cohort of patients suffering from critical limb ischemia that have been targeted for amputation. The Lifeline™ graft, coupled with cell injections into the lower limb will be available for 'no option' patients in an attempt to delay or even avoid amputation. Patients with severe critical limb ischemia that are interested in enrolling in this study can email here for more information: CLI_clinicaltrials@cytograft.com.

Updates will be posted on this website and will also be available on www.clinicaltrials.gov.